



ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

CENTRES OF EXCELLENCE IN STROKE CARE CONFIRMED AS FIRST TWO CLINICAL SITES

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”), a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to advise that EMVision has progressed in-principle agreements with the first two clinical sites for its upcoming clinical trials detailing how the studies will be conducted at these sites, being Royal Melbourne in VIC and Liverpool Hospital in NSW. Additional trial sites will be announced progressively. In addition, EMVision has appointed Avania Clinical a global leading medical technology Clinical Research Organisation (CRO) to support EMVision’s upcoming multi-centre study.

The Royal Melbourne Hospital is a comprehensive stroke care centre with a world renowned tertiary academic unit that provides leading care for patients across Victoria. Liverpool Hospital is one of the largest stroke referral centres in NSW, including an active endovascular clot retrieval service. Both sites have a special interest in providing excellence in the diagnosis and management of acute stroke patients. The sites will be activated progressively, commencing with Liverpool Hospital.

Avania is a leading, global full-service contract research organisation focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase.

EMVision is targeting study commencement this quarter, multi-centre ethics has been submitted to the Human Research Ethics Committee (HREC) and devices are in advance stage of commissioning. The Company will provide further information on the clinical trial plan shortly. Next steps include execution of clinical site contracts, completion of device commissioning, alongside ethics and governance approval to commence patient enrolment.

EMVision CEO, Dr Ron Weinberger commented “We are pleased with the progress being made and look forward to collaborating with our study sites as we move into the clinical trials. This is a key milestone in the development of our novel portable brain scanner as we seek to fulfill our mission of improving stroke patient outcomes.”

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 380
Andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.2 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.